Guidance

• Sales expected between $46.3m-$47.3m
• Pre-tax profit expected between $6.8m-7.3m
• Solid revenue growth from Australia and Malaysia/Singapore

Vita Life Sciences (ASX: VLS) has provided guidance for the half year ending 30 June 2026, anticipating sales between $46.3 million and $47.3 million, up from $45.5 million in H1 2025. The company expects pre-tax profit to be in the range of $6.8 million to $7.3 million, slightly higher than the $6.8 million reported in H1 2025. The anticipated revenue growth is attributed to established markets in Australia and Malaysia/Singapore, although this is partially offset by lower exports to China due to regulatory and channel dynamics. The company maintains a strong financial position with substantial cash reserves, no borrowings, and continued cash generation supporting strategic investments.

Sales: $46.3m-$47.3m, Pre-tax Profit: $6.8m-7.3m (H1 2026)

Vita Life Sciences expects solid revenue growth and pre-tax profit in line or slightly higher than the prior corresponding period, reflecting cost discipline and quality earnings.